Dr. Karen Kelly explains what a BRAFV600E fusion is in lung cancer. BRAFV600E is an important biomarker that can impact your treatment options. Talk to your doctor about comprehensive biomarker testing. Visit www.lung.org/braf for more information.

Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.